ORR was high and PFS was longer on entrectinib versus TTD on prior therapy. Furthermore, 65.8% of patients experienced clinically meaningful benefit based on GMI. This intrapatient analysis demonstrates comparative effectiveness of entrectinib in a rare, heterogeneous adult population.
Meletios A Dimopoulos, Antonio Palumbo, Paolo Corradini, Michèle Cavo, Michel Delforge, Francesco Di Raimondo, Katja Weisel, Albert Oriol, Markus Hansson, Angelo Vacca, María Jesús Blanchard, Hartmut Goldschmidt, Chantal Doyen, Martin Kaiser, Mario Petrini, Pekka Anttila, Anna Maria Cafro, Reinier Raymakers, Jesús F. San Miguel, Felipe de Arriba, Stefan Knop, Christoph Röllig, Enrique M. Ocio, Gareth J. Morgan, Neil Miller, Mathew Simcock, Teresa Peluso, Jennifer Herring, Lars Sternås, Mohamed H. Zaki, Philippe Moreau
Richard S. Finn, Shukui Qin, Masafumi Ikeda, Peter R. Galle, Michel Ducreux, Tae‐You Kim, Masatoshi Kudo, Ho Yeong Lim, В. В. Бредер, Philippe Merle, Ahmed O. Kaseb, Daneng Li, Yin‐Hsun Feng, Wendy Verret, Derek-Zhen Xu, Sairy Hernandez, Beiying Ding, Andrew X. Zhu, Ann‐Lii Cheng
María‐Victoria Mateos, Monika Engelhardt, Xavier Leleu, Mercedes Gironella, Holger W. Auner, Michèle Cavo, Meletios A Dimopoulos, Martina Bianco, G Merlo, Charles la Porte, Philippe Moreau
Sebastian Bauer, Robin L. Jones, Suzanne George, Hans Gelderblom, Patrick Schöffski, Margaret von Mehren, John Zalcberg, Yoon‐Koo Kang, Albiruni Ryan Abdul Razak, Jonathan C. Trent, Steven Attia, Axel Le Cesne, William M. Reichmann, Kam Sprott, Haroun Achour, Matthew L. Sherman, Rodrigo Ruiz‐Soto, Jean Yves Blay, Michael C. Heinrich
Discussion(0)
No comments yet. Be the first to comment.